ACHC

Acadia Healthcare (ACHC) is significantly outperforming the Medical sector, with year-to-date returns of 97.8% compared to the sector average of 0.2%. The company holds a Zacks Rank #2 (Buy) with improving analyst sentiment, as consensus earnings estimates have increased 3.5% in the past quarter. Brookdale Senior Living (BKD) is also highlighted as another outperforming Medical stock with a 0.7% return and 160% increase in EPS estimates.

IDEXX Laboratories is set to report Q3 2026 results on November 2, with consensus estimates projecting 7.5% revenue growth to $1.19 billion and 9.1% EPS growth to $3.71. The company's Companion Animal Group diagnostics, Water segment, and Livestock/Poultry/Dairy divisions are expected to drive performance, supported by volume growth and recurring revenues. IDEXX carries a Zacks Rank #2 with a +0.59% Earnings ESP, suggesting potential to beat estimates.

Danaher Corporation reported Q3 adjusted EPS of $2.11, beating estimates by 9.9%, with revenues of $6.55 billion in line with expectations. The company raised its 2026 adjusted EPS guidance to $8.57-$8.62 and expects 2.5% core revenue growth. Diagnostics segment sales jumped 17% driven by acquisitions, though respiratory testing revenues declined significantly from $500M to $350M year-over-year.

Molina Healthcare is projected to report a 60.9% earnings decline in Q3 2026 with revenues falling 4.8%. The company faces multiple headwinds including a 12.7% membership decline (63% drop in Marketplace enrollment), rising medical care ratio to 93%, and falling premium revenues and investment income. The stock has a negative Earnings ESP of -3.30% and Zacks Rank #4 (Sell), making an earnings beat unlikely.

Danaher Corporation is expected to report Q3 2026 revenues of $26.3 billion, up 8.2% year-over-year, driven by strength in Biotechnology, Diagnostics, and Life Sciences segments, plus the Masimo acquisition. However, rising input costs, product mix changes, and currency headwinds may pressure profits. The company has a positive Earnings ESP of +0.30% and Zacks Rank of 2 (Buy).

Elevance Health is projected to report Q3 2026 earnings on October 21, 2026, with consensus estimates showing a 22.7% year-over-year EPS decline to $4.66 per share and a 3% revenue decrease. The company faces challenges from declining premiums (-4.9%), reduced Commercial Individual and Medicaid membership, and a significant 23.9% plunge in Health Benefits operating income. Despite these headwinds, total expenses are expected to decline 5.5%, providing some offset.